Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perhexiline in HCM and Heart Failure
NCT02431221Phase 3Withdrawn
- Sponsor
- Heart Metabolics Limited
- Primary completion
- Jul 2017
01
Overview
Phase 3, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing Perhexiline Arm with Placebo Arm (2 arms). Primary endpoint: Subject Outcome Variable at 6 months. Status: withdrawn.
02
Drugs
perhexiline
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT02431221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02431221.